Necdet B. Gunsoy, PhDCorrespondence information about the author PhD Necdet B. GunsoyEmail the author PhD Necdet B. Gunsoy
,
Sarah M. Cockle, PhD
,
Steven W. Yancey, MSc
,
Oliver N. Keene, MSc
,
Eric S. Bradford, MD
,
Frank C. Albers, PhD
,
Ian D. Pavord, FMedSci
Open Access
Background
Mepolizumab significantly reduces exacerbations in patients with severe eosinophilic asthma. The early identification of patients likely to receive long-term benefit from treatment could ensure effective resource allocation.
Objective
To assess potential continuation rules for mepolizumab in addition to initiation criteria defined as 2 or more exacerbations in the previous year and blood eosinophil counts of 150 cells/μL or more at initiation or 300 cells/μL or more in the previous year.